^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | carboplatin (Tubulin polymerization promoter) + pegylated liposomal doxorubicin (Topoisomerase II inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy of chemotherapy according to BRCA status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse
Published date:
01/11/2023
Excerpt:
Patients with high-grade serous ovarian cancers at first platinum-sensitive relapse who received one of these doublets were included....Median progression-free survival was longer in BRCA mutated patients than in BRCA wild type patients when receiving carboplatin/pegylated liposomal doxorubicin without maintenance treatment (15.8 vs 11.8 months; p<0.001).
DOI:
10.1136/ijgc-2022-003993
